Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > I try to remind myself

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Nov 29, 2021 5:04pm

200 Views

Post# 34177525

RE:RE:RE:RE:RE:RE:I try to remind myself

Margin call? Where did you get that idea?The drop would have been a lot more significant,

I also dont think they are holding back market moving news.....I think they are as anxious as we are to release positive data when and IF confirmed ...Any tumor regression will be market moving without any need to put lipstick on the resulrs .....Some lipstick might be neeed if Phase 1 concludes with no sign of efficacy I think in that case they would issue a PR which would include a modified Phase 1 b-Phase 2 Protocol agreed to by FDA

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing